Scope of the Study
Cardiac troponins are one of the cardiac biomarkers or diagnostic markers centralized to myocardial infarction or heart muscle cell death diagnosis. It is measured in the blood to differentiate between unstable angina as well as myocardial infarction (heart attack) in patients with chest pain or acute coronary syndrome. There are various application of cardiac troponin including acute coronary syndrome, myocardial infarction and congestive heart failure.
The market study is being classified by Type (cTn T, cTn I and TnC), by Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure and Others Applications) and major geographies with country level break-up.
Abbott Diagnostics, Inc. (United States), bioMrieux SA (France), BG Medicine, Inc. (Cambodia), Ortho-Clinical Diagnostics, Inc. (United States), Singulex, Inc. (United States), Alere, Inc. (United States), Siemens Healthcare Diagnostics, Inc. (United States), Beckman Coulter, Inc. (United States), LifeSign LLC (United States) and Roche Diagnostics Corp. (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Randox Laboratories Ltd. (United Kingdom).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cardiac Troponin market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Cardiac Troponin market by Type, Application and Region.
On the basis of geography, the market of Cardiac Troponin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Laboratory Testing will boost the Cardiac Troponin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Up Surging Demand due to Cardiac Biomarkers for Cardiovascular Disease Diagnosis
- Increasing Incidences of Acute Coronary Syndrome (ACS)
- Fueling Demand Due To Advancements in the Cardiac Biomarkers
- Growing Demand for Point-Of-Care Cardiac Testing Kits
- Inadequate Reimbursements
- Dearth of Precision While Collecting Sample
- Huge Opportunity Due To Development of New Products
- Rising Awareness about Cardiac Troponin Biomarkers in Developing Countries
On 26th September 2018, Abbott has announced that its High Sensitive Troponin-I blood test is the first troponin test with CE Mark that can more accurately predict the chances of having a heart attack or other cardiac event potentially months to years in advance in people who otherwise appear healthy.
Key Target AudienceCardiac Troponin Manufactures, Cardiac Troponin Suppliers/ Distributors, Industry Association, Downstream Vendors, Government Regularity Bodies, Private and Government Research Organization and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase